The app for independent voices
Viking Therapeutics (NASDAQ: VKTX) Full Year 2025 Review
Fiscal year 2025 was not about near-term financial optics for Viking Therapeutics; it was about executing the most capital-intensive phase of its obesity strategy while preserving strategic flexibility. On that front, management delivered. The company dramatically accelerated spending to support late-stage clinical development, completed key enrollment milestones ahead of schedule, and exited the year with one of the strongest balance sheets in late-stage biotech.
Viking reported no revenue in 2025, which is fully expected for a clinical-stage company with its first commercial launch targeted for 2028. The income statement therefore needs to be interpreted purely through the lens of capital allocation and execution, not profitability.
For the full year 2025, Viking reported a net loss of $358.5 million, or $3.19 per share, compared with a net loss of $110.0 million in 2024. The year-over-year increase in losses was driven almost entirely by intentional R&D expansion, not structural inefficiency.
Research & Development expense surged to $345.0 million, up from $101.6 million in 2024
General & Administrative expense remained tightly controlled at $48.4 million, essentially flat year over year
This cost structure matters. Viking did not allow overhead to balloon alongside R&D. Instead, the company concentrated spending where it creates long-term value: global Phase 3 execution, manufacturing readiness, and regulatory preparation for VK2735.
The Q4 2025 numbers underscore this pattern. R&D expense in the quarter alone reached $153.5 million, reflecting peak trial activity, while G&A actually declined year over year. This is exactly what disciplined late-stage execution should look like.
The financial results cannot be separated from the operational achievements in 2025. During the year, Viking:
Initiated the Phase 3 VANQUISH program for subcutaneous VK2735
Completed enrollment in VANQUISH-1 ahead of schedule, exceeding the original 4,500-patient target
Advanced oral VK2735 through successful Phase 2 and secured FDA alignment to enter Phase 3 in Q3’26
Fully enrolled the VK2735 maintenance dosing study, with data expected in Q3’26
Continued development of VK2809 and prepared a new dual amylin/calcitonin receptor agonist (DACRA) IND
These are not incremental steps. They represent a transition from mid-stage clinical risk to late-stage regulatory execution, which justifies the magnitude of the 2025 R&D ramp.
Despite deploying more than $350 million in annual operating losses, Viking ended 2025 with $706 million in cash, cash equivalents, and short-term investments, down from $903 million at the end of 2024.
This decline reflects disciplined capital deployment rather than distress:
Total assets: $715.7 million
Total liabilities: just $76.7 million
No long-term debt
Stockholders’ equity: $639.1 million
Accounts payable and accrued liabilities increased as expected due to trial activity, but there are no balance-sheet red flags. Importantly, Viking remains fully funded through late 2026, covering:
Completion of VANQUISH-2 enrollment (expected 1Q26)
Phase 3 readiness for oral VK2735
Manufacturing scale-up and supply agreements
Early commercial infrastructure build
This balance-sheet resilience materially reduces financing risk ahead of pivotal data.
Weighted-average shares outstanding rose modestly to ~112.7 million in 2025, reflecting controlled equity issuance. Viking did not resort to aggressive dilution despite the elevated burn rate, underscoring management’s intent to preserve shareholder value ahead of key inflection points.
From an investor perspective, 2025 likely represents peak cash burn. As Phase 3 enrollment winds down and trial execution shifts toward data readout, incremental R&D intensity should plateau before the next step-up associated with commercialization.
From a capital markets standpoint, 2025 accomplished three critical objectives:
Removed enrollment risk from VK2735’s pivotal obesity trials
Validated oral VK2735 as Phase 3-ready, with FDA alignment
Preserved balance-sheet optionality, enabling Viking to remain independent through data
This combination materially changes Viking’s risk profile. The company exits 2025 no longer valued as a speculative obesity bet, but as a late-stage metabolic platform with visible regulatory and commercial pathways.
Summary of FY 2025:
Fiscal year 2025 should be viewed as a successful execution year, not a financial setback.
Losses widened because Viking chose to accelerate value creation
R&D spend was targeted, not bloated
G&A discipline remained intact
The balance sheet remains one of the strongest in the sector
By year-end, Viking had transformed from a promising obesity developer into a Phase 3-stage company with oral and injectable differentiation, FDA alignment, and sufficient capital to reach its next major valuation inflection.
In that context, 2025 did exactly what it needed to do.
Alpha Talon Guidance:
At Alpha Talon, we believe VK2735 and VK2809 demonstrate significant promise, supported by robust clinical trial results and an expanding body of patient-level data. Both programs target large, structurally durable markets with validated biology, and importantly, Viking has shown it can execute with discipline. FY2025 was a proof point: management delivered on enrollment, advanced manufacturing readiness, and preserved balance-sheet strength without compromising strategic flexibility.
If execution continues at the same standard demonstrated in FY2025, we view FDA approval as highly plausible, particularly for VK2735. In that scenario, Viking’s combination of late-stage de-risking, long-dated IP, and oral incretin optionality materially elevates its strategic value. We expect M&A interest from mega-cap pharma to intensify, as scarcity in next-generation metabolic assets becomes more acute.
We reiterate our base-case price target of $110 per share, representing an enterprise value of at least $11.5 billion. This target assumes no material deterioration in pipeline progress, financial standing, or management strategy and is framed over a 3–5 year horizon. Upside beyond this level is driven by stronger-than-expected execution, oral VK2735 durability, and strategic outcomes.
You can read more of our VKTX analysis here:
